• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PRASUGREL Drug Record

  • Summary
  • Interactions
  • Claims
  • PRASUGREL chembl:CHEMBL1201772 Approved

    Alternate Names:

    PRASUGREL
    LY-640315
    EFIENT
    EFFIENT®
    EFFIENT
    CS-747
    EFIENT®
    chembl:CHEMBL1201772
    pubchem.compound:6918456
    drugbank:06209
    rxcui:613391
    chemidplus:150322-43-3

    Drug Info:

    Year of Approval 2009
    Drug Class platelet aggregation inhibitors
    FDA Approval approved
    Drug Class small molecule
    Drug Indications antithrombotic
    (2 More Sources)

    Publications:

    Chan NC et al., 2014, Role of phenotypic and genetic testing in managing clopidogrel therapy., Blood
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
    Dovlatova et al., 2008, The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function., J. Thromb. Haemost.
    Abell LM et al., 2011, Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro., J Pharmacol Exp Ther
    Xiang Q et al., 2017, Genetic Variants of PEAR1 are Associated with Platelet Function and Antiplatelet Drug Efficacy: A Systematic Review and Meta-Analysis., Curr Pharm Des
    Xiang Q et al., 2013, Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics., Pharmacogenomics
  • PRASUGREL   PEAR1

    Interaction Score: 5.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28820077 23859572


    Sources:
    PharmGKB

  • PRASUGREL   P2RY12

    Interaction Score: 3.86

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name prasugrel, CS-747,Efient

    PMIDs:
    24951432 20938371 18485086


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • PRASUGREL   CYP2B6

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21828263


    Sources:
    PharmGKB FDA

  • PRASUGREL   NTRK1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28820077 23859572


    Sources:
    PharmGKB

  • PRASUGREL   CYP3A5

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21828263


    Sources:
    PharmGKB FDA

  • PRASUGREL   CYP2C9

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • PRASUGREL   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21828263


    Sources:
    PharmGKB

  • PRASUGREL   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • TEND: PRASUGREL

    • Version: 01-August-2011

    Alternate Names:
    PRASUGREL Primary Drug Name

    Drug Info:
    Drug Class platelet aggregation inhibitors
    Year of Approval 2009

    Publications:

  • TdgClinicalTrial: PRASUGREL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antithrombotic
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • PharmGKB: prasugrel

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
    Chan NC et al., 2014, Role of phenotypic and genetic testing in managing clopidogrel therapy., Blood
    Abell LM et al., 2011, Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro., J Pharmacol Exp Ther

  • TTD: Prasugrel

    • Version: 2020.06.01

    Alternate Names:
    D07IRF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201772

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Prasugrel

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21